Wilkinson Global Asset Management LLC Has $447,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Wilkinson Global Asset Management LLC lessened its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 5,740 shares of the company’s stock after selling 373 shares during the quarter. Wilkinson Global Asset Management LLC’s holdings in AstraZeneca were worth $447,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Sumitomo Mitsui Trust Holdings Inc. raised its holdings in AstraZeneca by 20.4% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 78,873 shares of the company’s stock valued at $5,344,000 after buying an additional 13,373 shares during the last quarter. Norden Group LLC acquired a new position in shares of AstraZeneca during the first quarter worth $255,000. Geneos Wealth Management Inc. grew its stake in shares of AstraZeneca by 44.2% in the first quarter. Geneos Wealth Management Inc. now owns 14,922 shares of the company’s stock worth $1,011,000 after purchasing an additional 4,573 shares during the last quarter. Gallacher Capital Management LLC raised its position in AstraZeneca by 2.8% during the 1st quarter. Gallacher Capital Management LLC now owns 5,431 shares of the company’s stock worth $368,000 after purchasing an additional 150 shares during the last quarter. Finally, ORG Partners LLC acquired a new position in AstraZeneca during the 1st quarter worth about $65,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $63.85 on Thursday. The stock has a market capitalization of $197.97 billion, a price-to-earnings ratio of 30.85, a PEG ratio of 1.32 and a beta of 0.47. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The stock’s 50 day moving average price is $78.45 and its two-hundred day moving average price is $78.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.